Chlormethine gel is effective for the treatment of skin lesions in patients with early‐ and late‐stage mycosis fungoides in clinical practice
暂无分享,去创建一个
M. Dalamaga | V. Nikolaou | A. Stratigos | L. Marinos | K. Lampadaki | M. Koumourtzis | A. Patsatsi | E. Georgiou | E. Papadavid
[1] I. Amitay-Laish,et al. Real-life experience with chlormethine gel for early-stage mycosis fungoides with emphasis on types and management of cutaneous side-effects# , 2021, The Journal of dermatological treatment.
[2] J. Scarisbrick,et al. Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA–IIA Mycosis Fungoides , 2021, Dermatology.
[3] E. Papadavid,et al. Chlormethine Gel in Combination with Other Therapies in the Treatment of Patients with Mycosis Fungoides Cutaneous T Cell Lymphoma: Three Case Reports , 2021, Advances in Therapy.
[4] O. Akilov,et al. The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma , 2021, American Journal of Clinical Dermatology.
[5] Ellen J. Kim,et al. Evaluating the Treatment Patterns of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: By-time Reanalysis of a Randomized Controlled Phase 2 Study. , 2020, Clinical lymphoma, myeloma & leukemia.
[6] B. Poligone,et al. Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis , 2020, JAAD case reports.
[7] P. Porcu,et al. Skindex-29 scores indicate poor quality of life in early stage mycosis fungoides. , 2020, Journal of dermatological science.
[8] D. Buckley,et al. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018 , 2018, The British journal of dermatology.
[9] J. Scarisbrick,et al. Update on skin directed therapies in mycosis fungoides. , 2019, Chinese clinical oncology.
[10] C. Klemke,et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. , 2017, European journal of cancer.
[11] Marianne Tawa,et al. Optimizing Care and Compliance for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma With Mechlorethamine Gel. , 2015, Clinical journal of oncology nursing.
[12] C. Prinsen,et al. Interpretation of Skindex-29 scores: cutoffs for mild, moderate, and severe impairment of health-related quality of life. , 2011, Journal of Investigative Dermatology.
[13] M. Chren,et al. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. , 1997, Archives of dermatology.
[14] Hodgkin Lymphoma. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .
[15] B. Strober,et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. , 2013, JAMA dermatology.
[16] D. Brizel,et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .